Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Biogen

SAGE Therapeutics

Binary events expected this month could have enormous implications for these drugmakers and their shareholders.

3 Biotech Stocks With Huge Catalysts in June

Vertex Pharmaceuticals has a lucrative suite of medicines for CF that will likely bring in approximately $6.8B in revenue in 2021. The early stage pipeline has multiple high risk, high reward programs.

Vertex Pharmaceuticals: An Undervalued Pipeline

Fate Therapeutics

Ionis Pharma

Novavax

A modest amount goes a long way when you invest in biotech stocks.

The Best Biotech Stocks to Buy With $500

Vertex is an immensely profitable company thanks to its near-monopoly on treatments for Cystic Fibrosis. Its latest CF therapy, Trikafta, made $3.8bn sales in FY20, and $1.2bn in Q121 - FY21 total revenue forecast is for $6.8bn - up 10% year-on-year.

Vertex: Exceptional CF Franchise And Undervalued Pipeline Send Strong Buy Signals

Amazon

Innovative Industrial Properties

History suggests a big decline is coming. But don't fret -- it's actually good news.

A Stock Market Crash May Be Near: 3 Stocks to Buy Hand Over Fist When It Happens

Apple

Cadence Design Systems

Generac Holdings

QUALCOMM

Growth seekers that like to minimize risk should explore these five large-cap stocks that the pros expect will gain 20% or more within a year.

5 Large-Cap Stocks With High Upside Potential

Alkermes

Bristol-Myers

Blueprint Medicines

Myovant Sciences

Provention Bio Inc

Sanofi

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

8 Biotech Stocks With Major Catalysts on the Horizon

Moderna

Seagen

Their revenue prospects are the ticket to future share price performance.

3 Biotech Stocks You'll Be Glad You Bought at These Prices

Block

Dogecoin is all hype with no substance. By comparison, this trio of unstoppable companies is the real deal.

Forget Dogecoin: These Unstoppable Stocks Are Much Smarter Buys

Following excellent Q1 2021 results, Vertex shares remain underpriced. The company has established itself as the dominant force in cystic fibrosis treatment, and they have only begun their global penetration.

Vertex: While The Market Remains Indifferent, Now Is The Time To Commit

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET. The audio portion of management's remarks will be available live through Vertex's website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex i

Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13

The cystic fibrosis specialist is moving into other lucrative areas.

This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon

Okta

These two stocks are attractive buy-and-hold picks for long-term investors.

Forget Penny Stocks: Buy These 2 Stocks Instead

Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.

Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Upwork Inc

Have $1,000 to Invest? Buy These 2 Growth Stocks Right Now

The biotech's improving fortunes relied on one drug.

Here's How Vertex Pharmaceuticals Beat Expectations in Q1

Teladoc

Unity Software

Don't count these ARK Invest ETF holdings out.

3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners

Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2021 Results - Earnings Call Transcript

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 16.41% over the past year to $2.98, which beat the estimate of $2.69.

Vertex Pharmaceuticals: Q1 Earnings Insights

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2021 and reiterated full-year 2021 guidance for product revenues. "In CF, our goal is that all eligible patients have access to and can benefit from CFTR modulators. In the first quarter, we continued to make significant progress towards this goal, and in so doing again delivered strong revenue and earnings growth,” said Reshma Kewalrama

Vertex Reports First-Quarter 2021 Financial Results

Gilead Sciences

After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks at cheaper prices.

2 Must-Own Biotech Stocks to Buy in May

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in all patients ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this extension of the indication, CF patients 12

Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene

On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.

What's in Store for Vertex (VRTX) This Earnings Season?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective NaV1.8 inhibitor, VX-548, into Phase 2 clinical development with clinical trials in patients with both visceral and non-visceral types of acute pain. The decision to move to Phase 2 was based on supportive Phase 1 data in healthy volunteers, including safety, tolerability and pharmacokinetics (PK). In these studies, the molecule exhibited a favorable profile at doses co

Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development

Exelixis

They're generating revenue now -- and more is on the way.

News for Vertex Pharmaceuticals Stock (VRTX)